Clinical Trial Update: Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma [Phase 3]

View source ↗

Summary

This Phase 3 trial compares ibrutinib plus rituximab against fludarabine phosphate, cyclophosphamide, and rituximab in previously untreated chronic lymphocytic …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia
• Small Lymphocytic Lymphoma

Drugs mentioned

• Cytoxan (cyclophosphamide)
• Fludara (fludarabine)
• IMBRUVICA (IBRUTINIB)
• Rituxan (rituximab)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Anemia, Chronic Lymphocytic Leukemia | Phase 3 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2023-08-14